PMID- 31138759
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20200807
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 39
IP  - 6
DP  - 2019 Jun 28
TI  - MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing 
      FGFR1 in gastric cancer.
LID - BSR20181258 [pii]
LID - 10.1042/BSR20181258 [doi]
AB  - MicroRNAs (miRNAs) are increasingly recognized as important therapeutic targets 
      in cancer. Here we aim to investigate the role of miR-198, a broad-spectrum tumor 
      suppressor, in gastric cancer (GC). MiR-198 overexpression was achieved by 
      transfection of miR-198 mimics, followed by evaluation of cell viability using 
      cell-counting kit 8. Cell cycle arrest and apoptosis were assessed by 
      Annexin-V-FITC/Propidium Iodide (PI) staining flow cytometry respectively. The 
      target of miR-198 was identified by bioinformatical analysis and confirmed by 
      dual-luciferase assay, along with real-time PCR and Western blot analyses of 
      target gene expression after transfection of miR-198 mimics. GC tissues were 
      characterized by miR-198 down-regulation. Restoration of miR-198 expression 
      attenuated GC cell proliferation and colony formation, meanwhile inducing 
      significant G(0)/G(1) arrest. Furthermore, combinatory therapy of cisplatin and 
      miR-198 induced greater anti-tumor effects than treatment with cisplatin single 
      therapy. We also identified fibroblast growth factor receptor 1 (FGFR1) as a 
      direct target gene of miR-198. Furthermore, FGFR1 silencing elicited a similar 
      tumor-suppressive effect as miR-198 overexpression. FGFR1 overexpression 
      antagonized the anti-tumor effects of miR-198 overexpression. MiR-198/FGFR1 axis 
      plays an important role in proliferation and apoptosis of GC. Therapies targeted 
      to miR-198 can potentially improve GC treatment.
CI  - (c) 2019 The Author(s).
FAU - Gu, Junxia
AU  - Gu J
AD  - Department of Digestive, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang City, Henan 
      Province, 471003, P.R. China.
FAU - Li, Xiaozhen
AU  - Li X
AD  - Department of Digestive, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang City, Henan 
      Province, 471003, P.R. China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Digestive, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang City, Henan 
      Province, 471003, P.R. China.
FAU - Jin, Zhe
AU  - Jin Z
AD  - Endoscopy Center, The First Affiliated Hospital, and College of Clinical Medicine 
      of Henan University of Science and Technology, Luoyang City, Henan Province, 
      471003, P.R. China.
FAU - Jin, Jianjun
AU  - Jin J
AUID- ORCID: 0000-0003-2625-428X
AD  - Department of Digestive, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang City, Henan 
      Province, 471003, P.R. China qcagax1@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190610
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN198 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
SB  - IM
MH  - Apoptosis/genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinogenesis/genetics
MH  - Cell Cycle Checkpoints/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Silencing
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Receptor, Fibroblast Growth Factor, Type 1/*genetics
MH  - Stomach Neoplasms/*genetics/pathology
PMC - PMC6558723
OTO - NOTNLM
OT  - FGFR1
OT  - gastric cancer
OT  - gene therapy
OT  - miR-198
OT  - miRNA
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2019/05/30 06:00
MHDA- 2020/08/08 06:00
PMCR- 2019/06/10
CRDT- 2019/05/30 06:00
PHST- 2018/07/25 00:00 [received]
PHST- 2019/04/09 00:00 [revised]
PHST- 2019/04/30 00:00 [accepted]
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
PHST- 2019/05/30 06:00 [entrez]
PHST- 2019/06/10 00:00 [pmc-release]
AID - BSR20181258 [pii]
AID - 10.1042/BSR20181258 [doi]
PST - epublish
SO  - Biosci Rep. 2019 Jun 10;39(6):BSR20181258. doi: 10.1042/BSR20181258. Print 2019 
      Jun 28.